BP11088 PCL, poly(ε-caprolactone), Hydroxyl Terminated, IV: 3.0–4.0 dl/g, Mw: 526–790 kDa

PCL, poly(ε-caprolactone), Hydroxyl Terminated, IV: 3.0–4.0 dl/g, Mw: 526–790 kDa Description

PCL, poly(ε-caprolactone), Hydroxyl Terminated, IV: 3.0–4.0 dl/g, Mw: 526–790 kDa is produced via ring-opening polymerisation of ε-caprolactone and features hydroxyl end groups. This synthesis route yields a controlled molecular weight distribution and predictable degradation profile, fundamental for applications in biomedical devices. The defined inherent viscosity contributes to reproducible mechanical properties and facilitates processing in diverse fabrication techniques.

PCL, poly(ε-caprolactone), Hydroxyl Terminated, IV: 3.0–4.0 dl/g, Mw: 526–790 kDa Applications

1.         Healthcare Applications
   - Used as a scaffold in tissue engineering to achieve uniform cell growth by leveraging controlled degradation rates.
   - Applied as an implant coating in bioresorbable devices to promote tissue integration by utilising predictable hydrolysis kinetics.

2.         Industrial & Research Applications
   - Used as a matrix in controlled-release drug formulations to achieve stable dosing by maintaining a consistent molecular weight.
   - Applied in additive manufacturing for biodegradable prototypes to ensure dimensional stability and predetermined degradation behaviour.

PCL, poly(ε-caprolactone), Hydroxyl Terminated, IV: 3.0–4.0 dl/g, Mw: 526–790 kDa Packing

The polymer powder is packaged in moisture-resistant, sealed aluminium pouches housed within a rigid, corrugated box to protect against mechanical impact and contamination. Storage recommendations call for a dry, room-temperature environment with low humidity and minimal light exposure. Anti-static measures are integrated into the packaging, and customised solutions are available for specific laboratory or industrial storage protocols.

Additional Information

PCL is a biodegradable polyester extensively studied in the field of biocompatible materials. Its controlled degradation and ease of processing make it a valuable material for biomedical applications such as tissue scaffolding and drug delivery systems. Understanding the relationship between molecular weight and intrinsic viscosity is critical for tailoring its performance.

The hydroxyl termination enhances the polymer's hydrophilicity and provides active sites for chemical functionalisation, improving its compatibility with hydrophilic matrices and facilitating covalent bonding in composite systems. This expands its utility in advanced manufacturing and bioactive material design. Ongoing research continues to refine processing techniques to optimise performance and reliability across diverse applications.

Regulatory Note: This material is designed for industrial and consumer applications. It is the customer's responsibility to ensure compliance with all applicable safety and regulatory requirements for their intended use.